Hani Al-Salami

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7204768/publications.pdf

Version: 2024-02-01

160 4,414 36 56
papers citations h-index g-index

162 162 162 3756
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Inflammatory bowel disease: clinical aspects and treatments. Journal of Inflammation Research, 2014, 7, 113.	3.5	321
2	Microparticles, microcapsules and microspheres: A review of recent developments and prospects for oral delivery of insulin. International Journal of Pharmaceutics, 2018, 537, 223-244.	5.2	206
3	Potential of insulin nanoparticle formulations for oral delivery and diabetes treatment. Journal of Controlled Release, 2017, 264, 247-275.	9.9	179
4	Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles. Frontiers in Pharmacology, 2018, 9, 1283.	3.5	159
5	Blood-Brain Barrier Dysfunction Precedes Cognitive Decline and Neurodegeneration in Diabetic Insulin Resistant Mouse Model: An Implication for Causal Link. Frontiers in Aging Neuroscience, 2017, 9, 399.	3.4	108
6	Oral insulin delivery: existing barriers and current counter-strategies. Journal of Pharmacy and Pharmacology, 2018, 70, 197-213.	2.4	103
7	Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. European Journal of Drug Metabolism and Pharmacokinetics, 2008, 33, 101-106.	1.6	102
8	Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus. International Journal of Pharmaceutics, 2018, 549, 201-217.	5.2	80
9	Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome. Frontiers in Pharmacology, 2018, 9, 1382.	3.5	78
10	A Systematic Review of the Valproic-Acid-Induced Rodent Model of Autism. Developmental Neuroscience, 2020, 42, 12-48.	2.0	76
11	Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods and Findings in Experimental and Clinical Pharmacology, 2008, 30, 107.	0.8	60
12	Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics. Journal of Pharmaceutical Innovation, 2014, 9, 150-157.	2.4	58
13	An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharmaceutical Development and Technology, 2015, 20, 702-709.	2.4	56
14	Probiotic Preâ€treatment Reduces Gliclazide Permeation (<i>ex vivo</i>) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats. Archives of Drug Information, 2008, 1, 35-41.	1.6	55
15	C2C12 cell model: its role in understanding of insulin resistance at the molecular level and pharmaceutical development at the preclinical stage. Journal of Pharmacy and Pharmacology, 2020, 72, 1667-1693.	2.4	53
16	Applications of superparamagnetic iron oxide nanoparticles in drug and therapeutic delivery, and biotechnological advancements. Beilstein Journal of Nanotechnology, 2020, 11, 1092-1109.	2.8	52
17	Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic \hat{l}^2 -cells. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 194-200.	2.8	50
18	Antimicrobial efficacy of nisin-loaded bacterial cellulose nanocrystals against selected meat spoilage lactic acid bacteria. Carbohydrate Polymers, 2021, 251, 117096.	10.2	50

#	Article	IF	CITATIONS
19	Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1290-1297.	2.8	49
20	The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Delivery and Translational Research, 2015, 5, 511-522.	5.8	48
21	Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes. AAPS PharmSciTech, 2015, 16, 45-52.	3.3	47
22	Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1642-1653.	2.8	47
23	The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation. Journal of Drug Targeting, 2018, 26, 551-562.	4.4	47
24	Development and validation of a new analytical HPLC method for simultaneous determination of the antidiabetic drugs, metformin and gliclazide. Journal of Food and Drug Analysis, 2019, 27, 315-322.	1.9	47
25	Advanced bile acid-based multi-compartmental microencapsulated pancreatic \hat{l}^2 -cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 588-595.	2.8	45
26	Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat. Journal of Diabetes Research, 2013, 2013, 1-8.	2.3	44
27	Probucol prevents blood–brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. Diabetes and Vascular Disease Research, 2019, 16, 87-97.	2.0	44
28	Designing antiâ \in diabetic \hat{l}^2 â \in cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis. Biotechnology Progress, 2016, 32, 501-509.	2.6	43
29	The influence of 3î±,7î±-dihydroxy-12-keto-5î²-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. European Journal of Drug Metabolism and Pharmacokinetics, 2008, 33, 137-142.	1.6	42
30	Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. European Journal of Drug Metabolism and Pharmacokinetics, 2009, 34, 43-50.	1.6	42
31	Novel chenodeoxycholic acid–sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An <i>in vitro</i> study. Journal of Microencapsulation, 2015, 32, 589-597.	2.8	42
32	The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4Âweeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Delivery and Translational Research, 2018, 8, 543-551.	5.8	42
33	Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. European Journal of Drug Metabolism and Pharmacokinetics, 2012, 37, 99-108.	1.6	41
34	Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Scientific Reports, 2020, 10, 106.	3.3	41
35	Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacological Reports, 2008, 60, 532-41.	3.3	39
36	Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. Journal of Microencapsulation, 2015, 32, 151-156.	2.8	38

#	Article	IF	Citations
37	The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable \hat{l}^2 -cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies. Drug Delivery and Translational Research, 2016, 6, 17-23.	5.8	35
38	The Influence of Stabilized Deconjugated Ursodeoxycholic Acid on Polymer-Hydrogel System of Transplantable NIT-1 Cells. Pharmaceutical Research, 2016, 33, 1182-1190.	3.5	34
39	The Effects of Ionic Gelation- Vibrational Jet Flow Technique in Fabrication of Microcapsules Incorporating \hat{I}^2 -cell: Applications in Diabetes. Current Diabetes Reviews, 2016, 13, 91-96.	1.3	33
40	Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Design, Development and Therapy, 2014, 8, 1221.	4.3	32
41	Primary Bile Acid Chenodeoxycholic Acid-Based Microcapsules to Examine \hat{l}^2 -cell Survival and the Inflammatory Response. BioNanoScience, 2016, 6, 103-109.	3.5	32
42	Flow vibration-doubled concentric system coupled with low ratio amine to produce bile acid-macrocapsules of \hat{l}^2 -cells. Therapeutic Delivery, 2016, 7, 171-178.	2.2	32
43	Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies. Expert Opinion on Drug Delivery, 2020, 17, 1361-1376.	5.0	31
44	Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Design, Development and Therapy, 2014, 8, 1003.	4.3	30
45	Mammary Gland Pathology Subsequent to Acute Infection with Strong versus Weak Biofilm Forming Staphylococcus aureus Bovine Mastitis Isolates: A Pilot Study Using Non-Invasive Mouse Mastitis Model. PLoS ONE, 2017, 12, e0170668.	2.5	30
46	Micro-Nano formulation of bile-gut delivery: rheological, stability and cell survival, basal and maximum respiration studies. Scientific Reports, 2020, 10, 7715.	3.3	30
47	Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3α,7α-dihydroxy-12-0X0-5β-cholanate, in healthy and diabetic rats. European Journal of Drug Metabolism and Pharmacokinetics, 2007, 32, 7-12.	1.6	29
48	A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes. Drug Delivery, 2016, 23, 2869-2880.	5 . 7	29
49	Lamotrigine and valproate pharmacokinetics interactions in epileptic patients. European Journal of Drug Metabolism and Pharmacokinetics, 2009, 34, 93-99.	1.6	28
50	Viability and topographical analysis of microencapsulated \hat{l}^2 -cells exposed to a biotransformed tertiary bile acid: an ex vivo study. International Journal of Nano and Biomaterials, 2016, 6, 74.	0.1	28
51	Innovative Microcapsules for Pancreatic β-Cells Harvested from Mature Double-Transgenic Mice: Cell Imaging, Viability, Induced Glucose-Stimulated Insulin Measurements and Proinflammatory Cytokines Analysis. Pharmaceutical Research, 2017, 34, 1217-1223.	3.5	28
52	Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 748-754.	2.8	28
53	An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic) Tj ETQq.	l 1 0,78431 4.3	14 rgBT /Over 27
54	Electrokinetic potential-stabilization by bile acid-microencapsulating formulation of pancreatic \hat{l}^2 -cells cultured in high ratio poly-L-ornithine-gel hydrogel colloidal dispersion: applications in cell-biomaterials, tissue engineering and biotechnological applications. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 1156-1162.	2.8	27

#	Article	IF	CITATIONS
55	Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration. Therapeutic Delivery, 2018, 9, 703-709.	2.2	27
56	Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. Pharmacological Research, 2019, 146, 104333.	7.1	27
57	Formulation and characterisation of insulin-loaded chitosan nanoparticles capable of inducing glucose uptake in skeletal muscle cells in vitro. Journal of Drug Delivery Science and Technology, 2020, 57, 101738.	3.0	27
58	The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes. Artificial Cells, Nanomedicine and Biotechnology, 2016, 44, 1508-1519.	2.8	26
59	Blood-brain barrier disturbances in diabetes-associated dementia: Therapeutic potential for cannabinoids. Pharmacological Research, 2019, 141, 291-297.	7.1	26
60	Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 28-32.	1.2	25
61	Pharmacological and Advanced Cell Respiration Effects, Enhanced by Toxic Human-Bile Nano-Pharmaceuticals of Probucol Cell-Targeting Formulations. Pharmaceutics, 2020, 12, 708.	4.5	25
62	Lyophilisation Improves Bioactivity and Stability of Insulin-Loaded Polymeric-Oligonucleotide Nanoparticles for Diabetes Treatment. AAPS PharmSciTech, 2020, 21, 108.	3.3	24
63	Biological Assessments of Encapsulated Pancreatic \hat{l}^2 -Cells: Their Potential Transplantation in Diabetes. Cellular and Molecular Bioengineering, 2016, 9, 530-537.	2.1	23
64	Antihypertensive agents do not prevent blood–brain barrier dysfunction and cognitive deficits in dietary-induced obese mice. International Journal of Obesity, 2017, 41, 926-934.	3.4	23
65	Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 269-280.	1.6	23
66	Bio-nanotechnological advancement of orally administered insulin nanoparticles: Comprehensive review of experimental design for physicochemical characterization. International Journal of Pharmaceutics, 2019, 572, 118720.	5.2	23
67	Transit Time Affects the Community Stability of <i>Lactobacillus </i> li>and <i>Bifidobacterium </i> Species in an <i>In Vitro </i> Model of Human Colonic Microbiotia. Artificial Cells, Blood Substitutes, and Biotechnology, 2011, 39, 351-356.	0.9	22
68	The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes. Journal of Microencapsulation, 2016, 33, 569-574.	2.8	22
69	Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 741-747.	2.8	22
70	The emerging role of bile acids as critical components in nanotechnology and bioengineering: Pharmacology, formulation optimizers and hydrogel-biomaterial applications. Biomaterials, 2022, 283, 121459.	11.4	22
71	Alginate-deoxycholic Acid Interaction and Its Impact on Pancreatic Î'-Cells and Insulin Secretion and Potential Treatment of Type 1 Diabetes. Journal of Pharmaceutical Innovation, 2016, 11, 156-161.	2.4	21
72	Alginate-combined cholic acid increased insulin secretion of microencapsulated mouse cloned pancreatic \hat{l}^2 cells. Therapeutic Delivery, 2017, 8, 833-842.	2.2	21

#	Article	IF	Citations
73	Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid. Therapeutic Delivery, 2018, 9, 811-821.	2.2	21
74	New Biotechnological Microencapsulating Methodology Utilizing Individualized Gradient-Screened Jet Laminar Flow Techniques for Pancreatic β-Cell Delivery: Bile Acids Support Cell Energy-Generating Mechanisms. Molecular Pharmaceutics, 2017, 14, 2711-2718.	4.6	20
75	Stability and biological testing of taurine-conjugated bile acid antioxidant microcapsules for diabetes treatment. Therapeutic Delivery, 2019, 10, 99-106.	2.2	19
76	The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus. Therapeutic Delivery, 2017, 8 , $401-409$.	2.2	18
77	Influence of Biotechnological Processes, Speed of Formulation Flow and Cellular Concurrent Stream-Integration on Insulin Production from β-cells as a Result of Co-Encapsulation with a Highly Lipophilic Bile Acid. Cellular and Molecular Bioengineering, 2018, 11, 65-75.	2.1	18
78	The effect of molecular weights of microencapsulating polymers on viability of mouse-cloned pancreatic \hat{l}^2 -cells: biomaterials, osmotic forces and potential applications in diabetes treatment. Pharmaceutical Development and Technology, 2018, 23, 145-150.	2.4	18
79	Environmental Transformation of Pharmaceutical Formulations: A Scientific Review. Archives of Environmental Contamination and Toxicology, 2019, 77, 155-161.	4.1	18
80	Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice. Current Drug Delivery, 2014, 11, 146-153.	1.6	17
81	Drug Permeation across the Blood-Brain Barrier: Applications of Nanotechnology. British Journal of Medicine and Medical Research, 2015, 6, 547-556.	0.2	17
82	Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects. European Journal of Pharmaceutical Sciences, 2017, 106, 1-9.	4.0	17
83	A second-generation micro/nano capsules of an endogenous primary un-metabolised bile acid, stabilized by Eudragit-alginate complex with antioxidant compounds. Saudi Pharmaceutical Journal, 2020, 28, 165-171.	2.7	17
84	A Review on Recent Advancement on Age-Related Hearing Loss: The Applications of Nanotechnology, Drug Pharmacology, and Biotechnology. Pharmaceutics, 2021, 13, 1041.	4.5	17
85	Oral gavage of nano-encapsulated conjugated acrylic acid-bile acid formulation in type 1 diabetes altered pharmacological profile of bile acids, and improved glycaemia and suppressed inflammation. Pharmacological Reports, 2020, 72, 368-378.	3.3	16
86	Quantification of BSA-loaded chitosan/oligonucleotide nanoparticles using reverse-phase high-performance liquid chromatography. Analytical and Bioanalytical Chemistry, 2018, 410, 6991-7006.	3.7	15
87	PAMPA model of gliclazide permeability: The impact of probiotic bacteria and bile acids. European Journal of Pharmaceutical Sciences, 2021, 158, 105668.	4.0	15
88	A novel biocompatible polymeric blend for applications requiring high toughness and tailored degradation rate. Journal of Materials Chemistry B, 2021, 9, 2532-2546.	5.8	15
89	Cellular assays and applied technologies for characterisation of orally administered protein nanoparticles: a systematic review. Journal of Drug Targeting, 2020, 28, 585-599.	4.4	14
90	Effectiveness of gelatine and chitosan spray coating for extending shelf life of vacuumâ€packaged beef. International Journal of Food Science and Technology, 2021, 56, 4026-4037.	2.7	14

#	Article	IF	Citations
91	Advancements in Assessments of Bio-Tissue Engineering and Viable Cell Delivery Matrices Using Bile Acid-Based Pharmacological Biotechnologies. Nanomaterials, 2021, 11, 1861.	4.1	14
92	Modulatory Nano/Micro Effects of Diabetes Development on Pharmacology of Primary and Secondary Bile Acids Concentrations. Current Diabetes Reviews, 2020, 16, 900-909.	1.3	14
93	DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 1-14.	1.6	13
94	Effectiveness of bacterial cellulose in controlling purge accumulation and improving physicochemical, microbiological, and sensorial properties of vacuumâ€packaged beef. Journal of Food Science, 2020, 85, 2153-2163.	3.1	13
95	Sio Micro-Nano Technologies of Antioxidants Optimised Their Pharmacological and Cellular Effects, ex vivo, inÂPancreatic β-Cells. Nanotechnology, Science and Applications, 2020, Volume 13, 1-9.	4.6	13
96	Pharmacological and Biological Study of Microencapsulated Probucol-Secondary Bile Acid in a Diseased Mouse Model. Pharmaceutics, 2021, 13, 1223.	4.5	13
97	An in vivo pharmacological study: Variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques. PLoS ONE, 2019, 14, e0214984.	2.5	12
98	Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic mice. Therapeutic Delivery, 2019, 10, 563-571.	2.2	12
99	Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acids. Therapeutic Delivery, 2019, 10, 573-583.	2.2	12
100	Impedance Spectroscopic Analysis of the Interidigitated Flexible Sensor for Bacteria Detection. IEEE Sensors Journal, 2020, 20, 12791-12798.	4.7	12
101	Development of orally administered insulin-loaded polymeric-oligonucleotide nanoparticles: statistical optimization and physicochemical characterization. Drug Development and Industrial Pharmacy, 2020, 46, 1238-1252.	2.0	12
102	Current status and applications of animal models in pre-clinical development of orally administered insulin-loaded nanoparticles. Journal of Drug Targeting, 2020, 28, 882-903.	4.4	12
103	Enhanced Bilosomal Properties Resulted in Optimum Pharmacological Effects by Increased Acidification Pathways. Pharmaceutics, 2021, 13, 1184.	4.5	12
104	Bile acid-polymer-probucol microparticles: protective effect on pancreatic \hat{l}^2 -cells and decrease in type 1 diabetes development in a murine model. Pharmaceutical Development and Technology, 2019, 24, 1272-1277.	2.4	11
105	The increasing role of pigment epithelium-derived factor in metastasis: from biological importance to a promising target. Biochemical Pharmacology, 2021, 193, 114787.	4.4	11
106	Testing and Characterization of Different Papers as Substrate Material for Printed Electronics and Application in Humidity Sensor. Sensors and Materials, 2019, 31, 2981.	0.5	11
107	Microencapsulation of Coenzyme Q10 and bile acids using ionic gelation vibrational jet flow technology for oral delivery. Therapeutic Delivery, 2020, 11, 791-805.	2.2	11
108	The Effects of Primary Unconjugated Bile Acids on Nanoencapsulated Pharmaceutical Formulation of Hydrophilic Drugs: Pharmacological Implications. Drug Design, Development and Therapy, 2021, Volume 15, 4423-4434.	4.3	11

#	Article	IF	CITATIONS
109	Typing of <i>Staphylococcus aureus</i> isolated from bovine mastitis cases in Australia and India. Australian Veterinary Journal, 2015, 93, 278-282.	1.1	10
110	Advanced and multifaceted stability profiling of the first-line antidiabetic drugs metformin, gliclazide and glipizide under various controlled stress conditions. Saudi Pharmaceutical Journal, 2020, 28, 362-368.	2.7	10
111	The Role of Drug Metabolites in the Inhibition of Cytochrome P450 Enzymes. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 881-890.	1.6	9
112	Histological effects of pharmacologically active human bile acid nano/micro-particles in Type-1 diabetes. Therapeutic Delivery, 2020, 11, 157-171.	2.2	9
113	Pharmacological effects of secondary bile acid microparticles in diabetic murine model. Current Diabetes Reviews, 2020, 16, .	1.3	9
114	Artificial Cell Encapsulation for Biomaterials and Tissue Bio-Nanoengineering: History, Achievements, Limitations, and Future Work for Potential Clinical Applications and Transplantation. Journal of Functional Biomaterials, 2021, 12, 68.	4.4	9
115	High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42. 1005-1011.	1.6	8
116	Transport and Biotransformation of Gliclazide and the Effect of Deoxycholic Acid in a Probiotic Bacteria Model. Frontiers in Pharmacology, 2019, 10, 1083.	3.5	8
117	Chenodeoxycholic Acid Pharmacology in Biotechnology and Transplantable Pharmaceutical Applications for Tissue Delivery: An Acute Preclinical Study. Cells, 2021, 10, 2437.	4.1	8
118	The Effects of Accelerated Temperature-Controlled Stability Systems on the Release Profile of Primary Bile Acid-Based Delivery Microcapsules. Pharmaceutics, 2021, 13, 1667.	4.5	8
119	Single-Cellular Biological Effects of Cholesterol-Catabolic Bile Acid-Based Nano/Micro Capsules as Anti-Inflammatory Cell Protective Systems. Biomolecules, 2022, 12, 73.	4.0	8
120	Evaluation of the water-holding and anti-spoilage effect of a bacterial cellulose nanocrystal coating for the storage of vacuum-packaged beef. Food Packaging and Shelf Life, 2022, 31, 100818.	7.5	8
121	The Effect of Deoxycholic Acid on Chitosan-Enabled Matrices for Tissue Scaffolding and Injectable Nanogels. Gels, 2022, 8, 358.	4.5	8
122	Decreased placental and transcellular permeation of cefuroxime in pregnant women with diabetes. Journal of Diabetes, 2016, 8, 238-245.	1.8	7
123	Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid. AAPS PharmSciTech, 2018, 19, 3009-3018.	3.3	7
124	\hat{l}^2 -Cyclodextrin-containing chitosan-oligonucleotide nanoparticles improve insulin bioactivity, gut cellular permeation and glucose consumption. Journal of Pharmacy and Pharmacology, 2021, 73, 726-739.	2.4	7
125	Bile acids as novel enhancers of CNS targeting antitumor drugs: a comprehensive review. Pharmaceutical Development and Technology, 2021, 26, 617-633.	2.4	7
126	Probucol Pharmacological and Bio-Nanotechnological Effects on Surgically Transplanted Graft Due to Powerful Anti-Inflammatory, Anti-Fibrotic and Potential Bile Acid Modulatory Actions. Pharmaceutics, 2021, 13, 1304.	4.5	7

#	Article	IF	Citations
127	Bile acid permeation enhancement for inner ear cochlear drug pharmacological uptake: bio-nanotechnologies in chemotherapy-induced hearing loss. Therapeutic Delivery, 2021, 12, 807-819.	2.2	7
128	Gut Microbiota Metabolism of Azathioprine: A New Hallmark for Personalized Drug-Targeted Therapy of Chronic Inflammatory Bowel Disease. Frontiers in Pharmacology, 2022, 13, 879170.	3.5	7
129	Probiotics Applications in Autoimmune Diseases. , 0, , .		6
130	Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women. BMC Pregnancy and Childbirth, 2013, 13, 188.	2.4	6
131	Role of metformin in various pathologies: state-of-the-art microcapsules for improving its pharmacokinetics. Therapeutic Delivery, 2020, 11, 733-753.	2.2	6
132	Fabrication techniques for the preparation of orally administered insulin nanoparticles. Journal of Drug Targeting, 2021, 29, 365-386.	4.4	6
133	Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid. PLoS ONE, 2021, 16, e0243858.	2.5	6
134	Chemotherapy-induced hearing loss: the applications of bio-nanotechnologies and bile acid-based delivery matrices. Therapeutic Delivery, 2021, 12, 723-737.	2.2	6
135	Auâ€NHC complexes with thiocarboxylate ligands: Synthesis, structure, stability, thiol exchange and in vitro anticancer activity. Applied Organometallic Chemistry, 0, , .	3.5	6
136	Potentials and Limitations of Bile Acids and Probiotics in Diabetes Mellitus. , $2011, \ldots$		5
137	Physicochemical characterisation of kafirins extracted from sorghum grain and dried distillers grain with solubles related to their biomaterial functionality. Scientific Reports, 2021, 11, 15204.	3.3	5
138	Pharmacokinetic and drug absorption profiles of the anti-hyperglycaemic agent gliclazide in oral tissue-targeted microcapsules in rats. Scripta Medica, 2020, 51, 15-20.	0.1	5
139	Polyelectrolytes Formulated with Primary Unconjugated Bile Acid Optimised Pharmacology of Bio-Engineered Implant. Pharmaceutics, 2021, 13, 1713.	4.5	5
140	Pharmaceutical \hat{A} formulation and polymer chemistry for cell encapsulation applied to the creation of a lab-on-a-chip bio-microsystem The rapeutic Delivery, 2021, , .	2.2	5
141	Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions. International Journal of Molecular Sciences, 2022, 23, 836.	4.1	5
142	The Effect of Diabetes and Hypertension on the Placental Permeation of the Hydrophilic Drug, Ranitidine. Placenta, 2016, 48, 144-150.	1.5	4
143	Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System. Journal of Endocrinology and Diabetes Mellitus, 0, , .	0.4	4
144	Influence of Bile Acids in Hydrogel Pharmaceutical Formulations on Dissolution Rate and Permeation of Clindamycin Hydrochloride. Gels, 2022, 8, 35.	4.5	4

#	Article	IF	CITATIONS
145	Pharmacological Dose-Effect Profiles of Various Concentrations of Humanised Primary Bile Acid in Encapsulated Cells. Nanomaterials, 2022, 12, 647.	4.1	4
146	Comparative evaluation of encapsulation using βâ€cyclodextrin versus freezeâ€drying for better retention and stabilizing of black Périgord truffle (<i>Tuber melanosporum</i>) aroma. Journal of Food Science, 2022, 87, 3482-3495.	3.1	4
147	Serological versus molecular typing of surface-associated immune evading polysaccharide antigens-based phenotypes of Staphylococcus aureus. Journal of Medical Microbiology, 2014, 63, 1427-1431.	1.8	3
148	Polydimethylsiloxane-customized nanoplatform for delivery of antidiabetic drugs. Therapeutic Delivery, 2020, 11, 415-429.	2.2	3
149	Cutting-edge biotechnological advancement in islet delivery using pancreatic and cellular approaches. Future Science OA, 2021, 7, FSO660.	1.9	3
150	Cognitive Deficits in Type-1 Diabetes: Aspects of Glucose, Cerebrovascular and Amyloid Involvement. Pharmaceutical Research, 2021, 38, 1477-1484.	3.5	3
151	Influence of the Main Filter on QRS-amplitude and Duration in Human Electrocardiogram. Measurement Science Review, 2019, 19, 29-34.	1.0	3
152	Taurine Grafted Micro-Implants Improved Functions without Direct Dependency between Interleukin-6 and the Bile Acid Lithocholic Acid in Plasma. Biomedicines, 2022, 10, 111.	3.2	3
153	3,5-Dibromophenyl-functionalised imidazolium salts and their corresponding [Au(NHC)2]+ complexes: synthesis, supramolecular chemistry and anti-cancer activity. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2021, 101, 227-242.	1.6	2
154	Dried blood spot: Utilizing dry blood for pharmacokinetic investigations - an old method with great future for therapeutic drug monitoring. Vojnosanitetski Pregled, 2018, 75, 1222-1225.	0.2	2
155	Pharmacological effects of novel microvesicles of basil, on blood glucose and the lipid profile: a preclinical study. Scientific Reports, 2021, 11, 22123.	3.3	2
156	Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study. Biomolecules, 2022, 12, 877.	4.0	2
157	Screening for Antidiabetic Activities. Methods in Molecular Biology, 2013, 1055, 207-218.	0.9	1
158	Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights. European Journal of Drug Metabolism and Pharmacokinetics, 2021, , 1.	1.6	1
159	'In vitro' assessments of microencapsulated viable cells as a result of primary bile acid-encapsulated formulation for inflammatory disorders. Scripta Medica, 2022, 53, 103-115.	0.1	1
160	A Functionalized Paper Strip-Based Platform for Rapid Detection of Anticancer Drug Concentrations. Journal of Sensors, 2021, 2021, 1-11.	1.1	O